Children with antibody-associated vasculitis, for instance, have a higher likelihood of upper airway disease and potentially severe lower airway disease.
Second-line ramucirumab and docetaxel after use of immune checkpoint inhibitors may improve some outcomes for patients with NSCLC. The study was published as a preprint and has not yet been peer reviewed.